Please ensure Javascript is enabled for purposes of website accessibility

Valneva gets FDA approval for shorter dosing schedule for vaccine

Valneva USA, which is based in Gaithersburg, received approval for an alternate immunization schedule of Ixiaro, the only vaccine approved in America for protection against the virus. (Valneva submitted photo)

Valneva USA, which is based in Gaithersburg, received approval for an alternate immunization schedule of Ixiaro, the only vaccine approved in America for protection against the virus. (Valneva submitted photo)

The U.S. subsidiary of a global biotech company has received Food and Drug Administration approval for a dramatically shorter dosing regimen for its Japanese encephalitis virus vaccine, allowing patients to protect themselves before travel in less time than previously required.

Valneva USA, which is based in Gaithersburg, received approval last week for an alternate immunization schedule of Ixiaro, the only vaccine approved in America for protection against the virus, the company announced.

The newly-approved alternate schedule provides for two doses administered seven days apart for adults between 18 and 65 years old. The previously approved schedule is two doses, 28 days apart, for people 2 months old and older. Either schedule requires taking the last dose at least seven days before travel.

Charles Daily, US general manager of Valneva, said in a news release that the shortened dose schedule would make it easier for people to get immunized prior to travel to affected areas.

 


To purchase a reprint of this article, contact reprints@thedailyrecord.com.